Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02168842 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Isradipine in Early Parkinson Disease
A Phase 3 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 3
- Development phase
- 336
- Enrollment target
NCT02168842: Completed Phase 3 study, sponsored by University of Rochester.
NCT02168842 is a Phase 3 study that has completed, run by University of Rochester. The registered enrollment target is 336 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02168842, a Phase 3 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 336 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether treatment with isradipine is effective in slowing the progression of Parkinson disease disability.
Primary Outcome
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the total (Part I-III) UPDRS score in the active treatment arm versus placebo between the baseline and 36 month visit. The change of UPDRS ranges from -30 to 80, larger value shows more disability from PD.
Interventions
- DRUG Isradipine
- DRUG Placebo (for Isradipine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2014-11 |
| Est. Completion | 2018-11 |
| Phase | Phase 3 |
What the finished NCT02168842 record still lists
NCT02168842 is an interventional study that assigns participants to a tested intervention. The registered 336 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 2 interventions - of which Isradipine is the first listed.
NCT02168842 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02168842 about?
NCT02168842 is a clinical study titled "Efficacy of Isradipine in Early Parkinson Disease". The purpose of the study is to determine whether treatment with isradipine is effective in slowing the progression of Parkinson disease disability.
What is the current status of trial NCT02168842?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 336 participants. The study started on 2014-11. Estimated completion is 2018-11.
What interventions are being tested in trial NCT02168842?
The interventions under investigation include: Isradipine (DRUG), Placebo (for Isradipine) (DRUG).
Who is sponsoring clinical trial NCT02168842?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02168842's enrollment target sits among peer trials
336 1060th of 2000 higher than 940 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03947385 · 336 participants · Phase 1
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- NCT03977207 · 336 participants · NA
A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients
- NCT04665206 · 336 participants · Phase 1
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
- NCT05124457 · 336 participants · Phase 2
DETERMINE: Detemir vs NPH
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia